Efficacy, safety, and tolerability of three regimens for prevention of malaria: A randomized, placebo-controlled trial in Ugandan schoolchildren

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Nankabirwa, Joaniter ^a   Cundill, Bonnie ^b   Clarke, Sian ^b   Kabatereine, Narcis ^c   Rosenthal, Philip J ^a,d   Dorsey, Grant ^a,d   Brooker, Simon ^b,e   Staedke, Sarah G ^a,b  

^a Uganda Malaria Surveillance Project   (Uganda)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MINISTRY OF HEALTH   (Uganda)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUOCOTEXIN; FANSIDAR; PLACEBO; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; NAUSEA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT OUTCOME; UGANDA; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; ANTIMALARIALS; CHILD; FEMALE; HUMANS; MALARIA; MALE; PLACEBOS; UGANDA;

EID: 78149462780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013438     Document Type: Article

References (47)

1. Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, et al. (2009) A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 6: e1000048.
2. Trape JF, Rogier C, Konate L, Diagne N, Bouganali H, et al. (1994) The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg 51: 123-137.
3. Lalloo DG, Olukoya P, Olliaro P (2006) Malaria in adolescence: burden of disease, consequences, and opportunities for intervention. Lancet Infect Dis 6: 780-793.
4. Brooker S, Clarke S, Snow RW, Bundy DA (2008) Malaria in African schoolchildren: options for control. Trans R Soc Trop Med Hyg 102: 304-305.
5. Brooker S (2009) Malaria control in schools: a toolkit on effective education sector responses to malaria in Africa. World Bank, Washington DC, USA and Partnership for Child Development, London, UK.
6. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, et al. (2007) Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial. PLoS Clin Trials 2: e20.
7. Gosling RD, Cairns ME, Chico RM, Chandramohan D (2010) Intermittent preventive treatment against malaria: an update. Expert Rev Anti Infect Ther 8: 589-606.
8. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, et al. (2009) Efficacy and safety of intermittent preventive treatment with sulfadoxinepyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374: 1533-1542.
9. Cisse B, Sokhna C, Boulanger D, Milet J, Bael H, et al. (2006) Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebocontrolled, double-blind trial. Lancet 367: 659-667.
10. Sokhna C, Cisse B, Bael H, Milligan P, Hallett R, et al. (2008) A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS One 3: e1471.
11. Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, et al. (2008) Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J 7: 123.
12. Cisse B, Cairns M, Faye E, O ND, Faye B, et al. (2009) Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One 4: e7164.
13. Clarke SE, Jukes MC, Njagi JK, Khasakhala L, Cundill B, et al. (2008) Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet 372: 127-138.
14. Barger B, Maiga H, Traore OB, Tekete M, Tembine I, et al. (2009) Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali. Trop Med Int Health 14: 784-791.
15. World Health Organisation (2010) WHO Policy recommendation on Intermittent Preventive Treatment during infancy with sulfadoxine-pyrimethamine (SPIPTi) for Plasmodium falciparum malaria control in Africa. Geneva.
16. Greenwood B (2006) Review: Intermittent preventive treatment-a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Trop Med Int Health 11: 983-991.
17. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, et al. (2009) Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci U S A 106: 9027-9032.
18. Menendez C, Bardaji A, Sigauque B, Romagosa C, Sanz S, et al. (2008) A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS One 3: e1934.
19. Okello PE, Van Bortel W, Byaruhanga AM, Correwyn A, Roelants P, et al. (2006) Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 75: 219-225.
20. Pullan RL, Bukirwa H, Staedke SG, Snow RW, Brooker S (2010) Plasmodium infection and its risk factors in eastern Uganda. Malar J 9: 2.
21. Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, et al. (2002) Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 360: 2031-2038.
22. Yeka A, Banek K, Bakyaita N, Staedke SG, Kamya MR, et al. (2005) Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med 2: e190.
23. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, et al. (2009) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 49: 1629-1637.
24. Francis D, Nsobya SL, Talisuna A, Yeka A, Kamya MR, et al. (2006) Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis 193: 978-986.
25. Gasasira AF, Kamya MR, Ochong EO, Vora N, Achan J, et al. (2010) Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J 9: 177.
26. Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ (2007) Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents Chemother 51: 3023-3025.
27. Tren R, Hess K, Bate R (2009) Drug procurement, the Global Fund and misguided competition policies. Malar J 8: 305.
28. Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ, et al. (2006) Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg 75: 836-842.
29. Campbell MJ, Julious SA, Altman DG (1995) Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. Bmj 311: 1145-1148.
30. Collett D (2003) Modelling survival data in medical research: Chapman and Hall/CRC.
31. Staedke SG, Jagannathan P, Yeka A, Bukirwa H, Banek K, et al. (2008) Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. Malar J 7: 107.
32. White NJ (2005) Intermittent presumptive treatment for malaria. PLoS Med 2: e3.
33. ter Kuile FO, van Eijk AM, Filler SJ (2007) Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. Jama 297: 2603-2616.
34. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, et al. (2009) Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 374: 1521-1532.
35. Wongsrichanalai C, Meshnick SR (2008) Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 14: 716-719.
36. World Health Organization (2008) Global malaria control and elimination: report of a meeting on containment of artemisinin tolerance. Geneva: World Health Organization.
37. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, et al. (2001) Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 358: 368-374.
38. Bell DJ, Nyirongo SK, Mukaka M, Zijlstra EE, Plowe CV, et al. (2008) Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. PLoS One 3: e1578.
39. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, et al. (2007) Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. Jama 297: 2210-2219.
40. Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, et al. (2007) Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised noninferiority trial. Lancet 369: 491-498.
41. Phillips-Howard PA, West LJ (1990) Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. Journal of the Royal Society of Medicine 83: 82-85.
42. Gimnig JE, MacArthur JR, M'Bang'ombe M, Kramer MH, Chizani N, et al. (2006) Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim- sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg 74: 738-743.
43. Markham LN, Giostra E, Hadengue A, Rossier M, Rebsamen M, et al. (2007) Emergency liver transplantation in amodiaquine-induced fulminant hepatitis. Am J Trop Med Hyg 77: 14-15.
44. Sturchler D, Mittelholzer ML, Kerr L (1993) How frequent are notified severe cutaneous adverse reactions to Fansidar? Drug Safety 8: 160-168.
45. Olliaro P, Mussano P (2003) Amodiaquine for treating malaria. Cochrane Database Syst Rev: CD000016.
46. Fanello CI, Karema C, van Doren W, Rwagacondo CE, D'Alessandro U (2006) Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults. Trop Med Int Health 11: 589-596.
47. Maiteki-Sebuguzi C, Jagannathan P, Yau VM, Clark TD, Njama-Meya D, et al. (2008) Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar J 7: 106